Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sequenom delays launch of SEQureDx Down syndrome test
Accordingly the company is no longer relying on the previously announced R&D test data and results. Sequenom has not changed its plans to develop in parallel its RNA-
Accordingly the company is no longer relying on the previously announced R&D test data and results. Sequenom has not changed its plans to develop in parallel its RNA-
Portuguese pharmaceutical company Bial-Portela & CA, and Eisai Europe Limited, the European subsidiary of Eisai Co, have reported that the novel once daily anti-epileptic Zebinix has received marketing
This design will enable patients to mix and administer exenatide once weekly from a pre-filled pen device, instead of the syringe and vial currently used in clinical trials,
PerClot Laparoscopic, a delivery configuration within the PerClot polysaccharide hemostatic system, was awarded CE approval in 2008. Perclot laparoscopic is a hemostatic system designed for applications in minimally
Walt Woltosz, chairman and CEO of Simulations Plus, said: “DDDPlus remains the only program of its kind in the world today. DDDPlus saves time and money. Rather than
Under this agreement, AMRI will test samples from its compound collection against several JNK kinases. These kinases may be implicated in the progression of Huntington’s disease (HD). AMRI
According to Medical Nutrition USA, the product, which is an enhanced formulation of Pro-Stat AWC, is designed for patients in long-term care facilities with advanced wounds, primarily pressure
According to United Therapeutics, the appointment of Mr Giltner brings the total number of directors to nine, six of whom are independent and not affiliated with the company.
Arisyn has recently announced its acquisition of a series of inhibitors with demonstrated preclinical efficacy against HIV, hepatitis C virus (HCV), HTLV-I, influenza virus, herpes viruses and cancer.
Unlike traditional synthetic RNAi, esiRNA incorporates a pool of hundreds of siRNAs against a single gene target. This new tool is designed to eliminate the trial and error